BRIEF-Bergenbio Announces Stopped Recruitment To The Bemcentinib Arm In UK Accord Covid Platform Trial

PUBLISHED: Tue, 30 Mar 2021 20:09:19 GMT
Share

March 30 (Reuters) – Bergenbio ASA:

* BERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB ARM IN UK ACCORD COVID PLATFORM TRIAL

* NO SAFETY CONCERNS HAVE BEEN IDENTIFIED.

* DECISION HAS BEEN MADE TO HALT UK RECRUITMENT AT 30 PATIENTS, SIMILAR NUMBER OF MATCHED CONTROLS, ENABLING A PROMPT ANALYSIS OF RESULTS

* DATA FROM ACCORD STUDY AND BERGENBIO’S PHASE II COVID-19 TRIAL STUDY WILL BE ANALYSED SEPARATELY

* BERGENBIO ASA – DATA FROM ACCORD STUDY AND BERGENBIO’S PHASE II COVID-19 TRIAL STUDY WILL BE ANALYSED IN COMBINATION IN A META-ANALYSIS

* BERGENBIO- PHASE II TRIAL OF BEMCENTINIB FOR TREATMENT OF COVID-19 IN HOSPITALISED PATIENTS IN SOUTH AFRICA AND INDIA COMPLETED RECRUITMENT Source text for Eikon: Further company coverage:

Sign Up for Our Newsletter Daily Update

Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html